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Background: Most countries carrying out campaigns of bovine tuberculosis (TB) eradication impose a ban on the
use of mycobacterial vaccines in cattle. However, vaccination against paratuberculosis (PTB) in goats is often
allowed even when its effect on TB diagnosis has not been fully evaluated. To address this issue, goat kids
previously vaccinated against PTB were experimentally infected with TB.
Results: Evaluation of interferon-γ (IFN-γ) secretion induced by avian and bovine tuberculins (PPD) showed a
predominant avian PPD-biased response in the vaccinated group from week 4 post-vaccination onward. Although
60% of the animals were bovine reactors at week 14, avian PPD-biased responses returned at week 16. After
challenge with M. caprae, the IFN-γ responses radically changed to show predominant bovine PPD-biased
responses from week 18 onward. In addition, cross-reactions with bovine PPD that had been observed in the
vaccinated group at week 14 were reduced when using the M. tuberculosis complex-specific antigens ESAT-6/CFP-
10 and Rv3615c as new DIVA (differentiation of infected and vaccinated animals) reagents, which further
maintained sensitivity post-challenge. Ninety percent of the animals reacted positively to the tuberculin cervical
comparative intradermal test performed at 12 weeks post-infection. Furthermore, post-mortem analysis showed
reductions in tuberculous lesions and bacterial burden in some vaccinated animals, particularly expressed in terms
of the degree of extrapulmonary dissemination of TB infection.
Conclusions: Our results suggest a degree of interference of PTB vaccination with current TB diagnostics that can
be fully mitigated when using new DIVA reagents. A partial protective effect associated with vaccination was also
observed in some vaccinated animals.
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Caprine tuberculosis (TB), caused either by Mycobacter-
ium bovis or M. caprae, and paratuberculosis (PTB),
caused by M. avium subsp. paratuberculosis (Map), are
endemic diseases in goat herds of the Iberian Peninsula
[1-3]. Both infections may have an impact in terms of
economic loss. Moreover, M. caprae and Map can be
transmitted between domestic hosts and wildlife species* Correspondence: bernat.perez@cresa.uab.cat
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distribution, and reproduction in any medium[2,4]. In addition, M. caprae is a zoonotic agent [5-7]
and Map has been associated with Crohn’s disease [8,9].
Control of PTB in small ruminants can be facilitated
by vaccination because the bacterial burden is greatly
reduced, containing the spread of the disease and pre-
venting clinical expression [10]. Furthermore, vaccin-
ation against PTB with Map-killed formulations has
been demonstrated to be an economically efficient strat-
egy to achieve control of the disease in small ruminants
[11-13] and cattle [14].
On the other hand, it has been shown that exposure to
M. avium can interfere with the diagnosis of M. tubercu-
losis complex organisms such as M. bovis or M. capraentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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natural infection with Map compromises TB diagnosis
in cattle [18,19] and goats [20]. Therefore, PTB could
also affect the specificity of diagnostic tests used in TB
control programs. The Spanish eradication program of
bovine TB expressly forbids the use of Map-based vac-
cines in cattle because of this potential interference with
TB diagnostics. In contrast, vaccination against PTB in
goats is permitted with the exception of a minority of
herds that are subjected to TB control in some regions.
To date, the potential effect of Map-based vaccines on
the diagnosis of TB has only been investigated post hoc
under field conditions [21,22].
It has been reported that TB diagnostic tests currently
used in cattle, such as the skin test or the interferon-
gamma (IFN-γ) assay, can be used for diagnosis of TB in
goats [23-25]. Moreover, in recent years, new IFN-γ
assays based on antigens secreted by active growing ba-
cilli, such as the peptide cocktail ESAT-6/CFP-10 (E/C)
or Rv3615c [26,27], have been developed as alternatives
to bovine and avian tuberculins. These antigens are not
present in either M. bovis BCG or Map and can be
viewed as novel DIVA (differentiation of infected and
vaccinated animals) regents able to distinguish TB-
infected from TB- or PTB-vaccinated animals.
The aim of the present work was to assess how vaccin-
ation against Map affects standard and novel diagnostic
tests in goats. Thus, we evaluated the interference of a
commercial Map-killed vaccine on TB diagnosis in goats
vaccinated and subsequently challenged with M. caprae.
The objectives of the present work were: (1) to investi-
gate the possible interference of vaccination before and
after M. caprae infection on TB diagnostic tests (single
and comparative skin tests and IFN-γ assay); (2) to as-
sess the usefulness of DIVA-peptide candidates E/C and
Rv3615c; and (3) to evaluate immunological and post-
mortem indicators of the effects of PTB vaccination on
M. caprae infection.
Results
Assessment of diagnostic tests
The effect of Map vaccination and subsequent infection
with M. caprae on TB diagnostic assays based on cell-
mediated immunity was assessed during this study. Four
vaccinated goats were subjected to the tuberculin cer-
vical comparative intradermal test (CIT) at week 14, and
all were negative for TB and correctly classified as avian
reactors. However, the four goats were classified as posi-
tive for TB if only the bovine tuberculin (PPD-B) result
(as a single intradermal tuberculin test [SIT]) was con-
sidered (data not shown), which indicated that the speci-
ficity of the SIT was severely compromised by PTB
vaccination. The skin test was repeated in all goats at
week 26 (12 weeks post-infection [wpi] with M. caprae).In the vaccinated group, 9 of 10 goats were bovine reac-
tors (positive for TB) using the CIT (1 goat was an avian
reactor), but all goats were classified as TB reactors by
applying the SIT interpretation. All unvaccinated goats
were positive for TB with both tests (Table 1). Differ-
ences between groups in the mean specific thickness in-
crease for each tuberculin were statistically significant
only for ΔPPD-A (avian tuberculin), with a mean in-
crease of 14.4 mm (11.9–17, 95% CI) in the vaccinated
group versus a mean increase of 10.8 mm (8.8–12.9, 95%
CI) in the control group (p < 0.05) (Table 1). Differences
were also found in the mean value of ΔPPD-B minus
ΔPPD-A. This value was significantly lower in the vacci-
nated group (5.2 mm, 2.9–7.5, 95% CI) than in the un-
vaccinated group (10.3 mm, 8.8–11.9, 95% CI)
(p < 0.005) (Table 1).
The tuberculin-based IFN-γ test was performed every
2 weeks throughout the experiment. The kinetics of
IFN-γ responses of the vaccinated group showed a PPD-
A-biased response, which switched to a PPD-B-biased
mean response 4 weeks after M. caprae infection (at
week 18 of the experiment) (Figure 1). In the unvaccin-
ated control group, a PPD-B-biased response was
obtained 4 weeks after M. caprae infection, whereas no
response was observed before this time point in any of
the goats (data not shown). When the results were ana-
lyzed individually (Table 2), Map-vaccinated goats began
showing responses to PPD-A (“avian reactors”) at week
2 after vaccination (2 of 10 goats), and all of them subse-
quently became avian reactors between weeks 4 and 10.
However, 1 of 10 goats became a “bovine reactor” (posi-
tive to PPD-B) at week 12 of the experiment (12 weeks
post-vaccination [wpv]), and this figure rose to 6 of 10 at
week 14, in the blood samples taken just before infection
with M. caprae. Interestingly, in the next blood sampling
at 2 wpi (week 16), again 8 of 10 goats showed a stron-
ger reaction to PPD-A than to PPD-B, and the 2 other
vaccinated goats were negative to both tuberculins. By
contrast, at week 18 (4 weeks after M. caprae challenge),
9 of 10 (90%) of the vaccinated goats were bovine reac-
tors. At week 20, all goats were positive to PPD-B (bo-
vine reactors), and these results were maintained during
the rest of the trial with the exception of one goat that
tested bovine-negative at week 24 and another that was
an avian reactor at week 28 (see Table 2). In the unvac-
cinated group, all goats were bovine reactors at week 18
and remained so until the end of the experiment, with
the exception of two goats that were negative at week 24
but returned to positivity at weeks 26 and 28 (data not
shown).
Next, we assessed the interference of Map vaccination
with the IFN-γ assay by employing the defined antigen
reagents E/C and Rv3615c. Responses were assessed at
the same five time points described in the Materials and
Table 1 Increases in skin-fold thickness and corresponding results of tuberculin skin tests
Group Goat ΔAv a ΔBov b ΔBov-ΔAv CIT SIT
Vaccinated 1 14.2 22.6 8.4 + +
2 15.2 26.0 10.8 + +
3 17.6 20.9 3.3 + +
4 10.6 19.5 8.9 + +
5 16.2 18.1 1.9 + +
6 14.5 16.5 2.0 + +
7 6.2 14.2 8.0 + +
8 14.6 17.4 2.8 + +
9 13.2 19.4 6.2 + +
10 22.0 21.7 −0.3 - e +
Mean (95% CI) 14.4 (11.9-17)*f 19.6 (17.5-21.7) 5.2 (2.9-7.5)**
Unvaccinated 11 11.3 19.7 8.4 + +
12 15.0 24.1 9.1 + +
13 3.3 14.5 11.2 + +
14 9.8 18.3 8.5 + +
15 11.3 21.2 9.9 + +
16 8.7 24.6 16.0 + +
17 11.4 19.1 7.7 + +
18 10.1 22.5 12.4 + +
19 14.6 25.8 11.2 + +
20 12.7 21.6 8.9 + +
Mean (95% CI) 10.8 (8.8-12.9) 21.1 (19–23.2) 10.3 (8.8-11.9)
Test results are scored as (−) negative or (+) positive.
a ΔAv, increase in skin-fold thickness (mm) 72 h after PPD-A application.
b ΔBov, increase in skin-fold thickness (mm) 72 h after PPD-B application.
c CIT, Cervical comparative intradermal test.
d SIT, Single intradermal test.
e Avian reactor.
f *p < 0.05; **p < 0.005 (unpaired two-sample Student’s t-test).
Figure 1 Kinetics of IFN-γ released after stimulation of whole blood with tuberculins in the vaccinated group. Avian tuberculin (PPD-A,
▲), bovine tuberculin (PPD-B, ■). Results are expressed as mean ΔOD450 (mean of OD450 of antigen-stimulated values with unstimulated values
subtracted) ± 95% confidence interval.
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Table 2 Results of the standard IFN-γ assay (Bovigam™)
Goat Week
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
1 N N Av Av Av Av Av Av Av Bov Bov Bov Bov Bov Bov
2 N Av Av Av Av Av Av Av Av Bov Bov Bov Bov Bov Bov
3 N N Av Av Av Av Av Bov Av Bov Bov Bov Bov Bov Bov
4 N N Av Av Av Av Bov Bov Av Bov Bov Bov N Bov Bov
5 N N Av Av Av Av Av Bov N Bov Bov Bov Bov Bov Bov
6 N N Av Av Av Av Av Av Av Bov Bov Bov Bov Bov Bov
7 N N Av Av Av Av Av Bov N Bov Bov Bov Bov Bov Av
8 N N Av Av Av Av Av Av Av Av Bov Bov Bov Bov Bov
9 N Av Av Av Av Av Av Bov Av Bov Bov Bov Bov Bov Bov
10 N N Av Av Av Av Av Bov Av Bov Bov Bov Bov Bov Bov
Test results are classified as: Av, positive response to PPD-A; Bov, positive response to PPD-B; or N, negative.
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were defined as TB-negative (ΔOD450 ≤ 0.05) according
to the test results. At weeks 20, 24, and 28, 90%, 100%,
and 70% of vaccinated goats were positive with the E/C
cocktail and 100%, 90%, and 80% were positive with
Rv3615c, respectively (Table 3). However, these propor-
tions increased to 100%, 100%, and 90% at weeks 20, 24,
and 28, respectively, when the E/C and Rv3615c results
were considered together. Very similar results were
obtained in the unvaccinated group, in which 100%,
80%, and 90% of goats were positive to E/C at weeks 20,
24, and 28, respectively; 100%, 80%, and 80% of goats
were positive to Rv3615c; and 100%, 80%, and 90% of
goats were positive again when combining the results for
both antigens at the same time points (data not shown).
Seropositivity to Map was assessed using the Paratub.
Serum-S ELISA kit (Institut Pourquier, Montpellier,
France) applying the cut-off defined above. All goats
(n = 20) were negative at week 0. Unvaccinated goatsTable 3 Results of the IFN-γ assay using two DIVA reagents: E
Goat Week
14 16 20
E/C Rv3615c E/C Rv3615c E/C
1 - - - - +
2 - - - - +
3 - - - - +
4 - - - - +
5 - - - - +
6 - - - - -
7 - - - - +
8 - - - - +
9 - - - - +
10 - - - - +
Test results are classified as (−) negative or (+) positive.also remained negative during the experiment (data not
shown). In contrast, 1 of 10 (10%) and 5 of 10 (50%) vac-
cinated goats were positive or doubtful at weeks 14 (0
wpi) and 28 (14 wpi), respectively, with different degrees
of intensity (Table 4). The mean intensity of antibody re-
sponse (%S/P) increased moderately, but was statistically
significant (p < 0.05), from 20% (4%–36%, 95% CI) at
week 14 to 55% (19%–91%, 95% CI) at week 28 (2 weeks
after CIT).Pathology and bacteriology
At necropsy on week 28 (14 wpi), visible pathology typ-
ical of TB was observed in the lungs and pulmonary
lymph nodes (LN) of all animals irrespective of their
vaccination status. Of the seven lung lobes evaluated,
the vaccinated group presented an average of three lobes
with gross lesions (2–4, 95% CI), slightly lower than the
mean of four lobes (3–5, 95% CI) found in theSAT-6/CFP10 (E/C) and Rv3615c
24 28
Rv3615c E/C Rv3615c E/C Rv3615c
+ + - + -
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + - +
+ + + - +
+ + + - -
+ + + + +
+ + + + +
Table 4 Seroreactivity to Map (Paratub.Serum-S™ ELISA)
Goat Week
0 14 28a
Result S/P b Result S/P Result S/P
1 - 0% - 30% + 130%
2 - 0% - 0% - 0%
3 - 1% - 8% d 51%
4 - 0% - 3% + 113%
5 - 0% - 36% + 56%
6 - 0% - 16% - 19%
7 - 0% - 6% - 4%
8 - 0% + 86% + 157%
9 - 0% - 4% - 9%
10 - 0% - 11% - 11%
Test results are classified as (−) negative, (+) positive, or (d) doubtful.
a Two weeks after CIT.
b S/P, Seroreactivity rates.
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cally significant (p = 0.324).
The mean log10-transformed volume of gross lesions
in lungs was similar in the unvaccinated (1.3 log10 cm
3;
1–1.7, 95% CI) and vaccinated (1.1 log10 cm
3; 0.5–1.6,
95% CI) groups (p = 0.470), but values were spread over
a wider range in the vaccinated group. By contrast, sta-
tistically significant differences between vaccinated and
control goats were found after assessing the gross path-
ology in LN: The unvaccinated animals presented with a
mean log10-transformed volume of visibly affected tissue
of 3.9 log10 mm
3 (3.6–4.3, 95% CI) compared with 3.3
log10 mm
3 (2.7–3.8, 95% CI) obtained in the vaccinated
group (p < 0.05). The individual pathological parameters
are represented in Figure 2A and B.
In addition, none of the vaccinated goats showed
extrapulmonary gross lesions, whereas dissemination
was observed in 4 of 10 unvaccinated goats that pre-
sented with gross lesions beyond the thoracic area
(2 goats with lesions in retropharyngeal LN, 2 goats with
lesions in mesenteric LN, and 1 goat with lesions in the
spleen). These lesions were histopathologically con-
firmed to be tuberculous.
In three animals, focal lesions were also found in the
LN draining the Map vaccine inoculation point (axillary,
prescapular, or subcutaneous LN). These lesions were
attributed to the vaccine inoculation because of their
localization and histological characteristics: lesions pre-
dominantly necrotizing rather than granulomatous,
without Langerhans cells, but surrounded by dispersed
polymorphonuclear cells and abundant fibrosis.
Finally, the mycobacterial load in LN was calculated as
log10 cfu/g. The bacterial burden in the pulmonary and
retropharyngeal LN of all animals (n = 20) ranged from
2 to 4 log10 cfu/g (Figure 2C). The total bacterial load inthe unvaccinated group was 3.5 log10 cfu/g (3.2–3.7, 95%
CI), slightly higher than that in the vaccinated group
(3.1 log10 cfu/g, 2.7–3.6, 95% CI). However, this differ-
ence was not statistically significant (p = 0.203).
Cross-sectional analysis
To evaluate the vaccine effect in terms of heterologous
protection, post-mortem parameters were also assessed
in combination. A mild positive correlation between
bacteriological and pathological findings was found by
correlating individual logarithmic values of bacterial load
and total volume of visible lesions (r = 0.386, p < 0.05).
However, a higher dispersion of individual values was
observed in the vaccinated group compared with the un-
vaccinated group (Figure 3A), and a stronger positive
correlation was found when only vaccinated goats were
assessed (r = 0.523, p < 0.05), whereas results obtained
from unvaccinated goats did not show significant corre-
lations (r = -0.274, p > 0.05).
To further analyze the reductions in post-mortem
parameters associated with vaccination, a cross-sectional
study was performed on the basis of the criteria
described in a previous TB vaccine efficacy trial [28].
The vaccinated animals were divided into two subgroups
according to the severity of the pathology and the bac-
terial burden. This division was established by combin-
ing the data of the total volume of gross lesions and the
bacterial load in LN. The mean between the volume of
lesions (log10 cm
3) and the bacterial load (log10 cfu) was
thereby calculated for each animal, and the cut-off point
to classify the animals into categories of distinct vaccin-
ation outcomes was defined as the minimum value
obtained among the unvaccinated control animals
(Figure 3A). Subsequently, a “vaccine responders” (VR)
subgroup of five goats and another “vaccine non-
responders” (VNR) subgroup of five goats were defined
(Figure 3A, open and closed circles).
Once the subgroup division was applied as described
in the previous paragraph, the assumed pathological and
bacteriological differences between the new subgroups
were checked. The total volume of visible lesions and
the bacterial load were significantly lower in VR com-
pared with VNR and unvaccinated control (UC) animals
(p < 0.05).
The release of IFN-γ specific to E/C, Rv3615c, and
PPD-B at week 28 (performed just before sacrifice of the
animals) was also compared between the VR, VNR, and
UC groups (Figure 3B). A significantly lower IFN-γ to E/
C response was found in VR animals than in VNR and
UC animals (p < 0.05). The relationship between E/C-
specific IFN-γ response and disease severity was con-
firmed by finding a positive correlation of IFN-γ-specific
secretion to E/C at week 28 with the total volume of
gross lesions (Spearman rank = 0.546, p < 0.01) and the
Figure 2 Post-mortem analysis as measured by gross pathology and bacterial burden. Results are plotted for individual goats. (A) Total
volume of visible lesions (VL) in lungs as log10 cm
3. (B) Total volume of VL in respiratory lymph nodes (LN) as log10 mm
3. (C) Bacterial load as
log10 cfu/g. (●) vaccinated goats, (■) unvaccinated goats. Horizontal lines indicate median values. Significance determined by unpaired t-test: *p <
0.05.
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[Spearman rank = 0.379, p = 0.050], data not shown).
Discussion and conclusions
The present experimental trial in goats was designed
with the aim to determine the effects of Map vaccination
on current TB diagnostic tests and assess the effects of
PTB vaccination on TB infection.
All experimental goats became infected irrespective of
vaccination status. However, a reduction in pulmonary
pathology was observed in some vaccinated individuals
compared with the unvaccinated group. Another re-
markable finding was that all vaccinated goats showed
only TB lesions at the site of infection (i.e., lungs and
associated LN) in contrast to the increased dissemin-
ation frequency in non-vaccinated animals. This findingFigure 3 Protective efficacy measured by post-mortem results, and cr
outcome. (A) Correlation between pathological and bacteriological param
threshold defined to divide vaccine responders (VR) and vaccine non-respo
unvaccinated controls (UC), (○) VR goats, (●) VNR goats. (B) Specific IFN-γ r
stimulation of whole blood with PPD-B, ESAT-6/CFP-10, or Rv3615c. Results
are expressed as mean ΔOD450 ± 95% confidence interval. Significances deis analogous to the results of subcutaneous vaccination
against PTB with the Map-killed vaccine in cattle subse-
quently challenged with Map. The vaccine in those stud-
ies induced systemic immunity, preventing bacteremia
and, consequently, dissemination of mycobacteria from
the primary infection site. However, they did not prevent
the establishment of the initial infection [10]. Similar
results were obtained in another experimental infection
with M. caprae in which three of six (50%) infected
goats showed gross TB lesions in mesenteric LN [29].
This outcome is also consistent with findings observed
in field cases of TB in goats [30-32].
In this sense, the present results indicate a certain de-
gree of containment of dissemination of the infection
from the primary complex, even when a significant re-
duction in the bacterial load in pulmonary drainage LNoss-sectional comparison of IFN-γ results with vaccination
eters of all goats (n = 20). Dashed line (y = −x + 4.16) indicates the
nders (VNR). Symbols represent vaccine cross-protection outcome: (■)
esponses at week 28 of the experiment as determined by ELISA after
are represented in relation to vaccine cross-protective outcome and
termined by non-parametric Kruskal-Wallis test: *p < 0.05.
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may not be sufficient to effectively prevent excretion of
mycobacteria and horizontal transmission within a herd.
The role of the immunological status of vaccinated ani-
mals, especially the T-cell response, can be critical in terms
of control or spread of the infection from the primary re-
spiratory focus. Similarly, Hope et al. found few lesions at
necropsy and smaller bacterial loads in LN in calves inocu-
lated with M. avium and subsequently challenged with M.
bovis [17]. The authors suggested that T-cell responses
resulting from M. avium infection enhanced a protective
secondary response after challenge with M. bovis.
After conducting cross-sectional analysis, we found
positive correlations of the IFN-γ response to E/C with
pathology severity, and more weakly with bacterial load.
A similar result was obtained with the single ESAT-6-
specific IFN-γ response compared with pathology scores
in goats [30] and calves [33]. Furthermore, a positive
correlation between the E/C-specific IFN-γ response and
bacterial load was also previously described in goats [24]
and cattle [34]. Moreover, after analyzing post-mortem
data, clear differences in the pathological and bacterio-
logical results were found within the vaccinated group.
The IFN-γ responses of vaccinated goats with low and
high post-mortem scores (VR and VNR, respectively)
were compared. The significantly lower E/C-specific
IFN-γ responses obtained in VR animals demonstrated
the capacity of this immunological biomarker to predict
the severity of the disease and, by default, to predict the
vaccine outcome.
In terms of assessment of TB diagnostic tests, we have
adapted the diagnostic tests routinely used in cattle in
bovine TB eradication programs. We have also intro-
duced new DIVA reagents to perform the IFN-γ assay.
Sensitivities obtained in all tests were higher than those
obtained in previous studies in naturally infected goats
[20,23]. Notwithstanding this, the enhanced sensitivity
described in these works when combining skin tests and
IFN-γ tests was also confirmed in the present experi-
mental trial.
The sensitivities of skin tests performed in vaccinated
animals (100% and 90% for SIT and CIT, respectively),
were higher than those obtained in another study carried
out with goat herds naturally co-infected with TB and
PTB (71% and 42.7%, respectively) [20]. In this work, the
authors reported many animals with false-negative CIT
results that showed higher skin-fold thickness to PPD-A
than to PPD-B. It is important to note that the sensitiv-
ity of CIT in the present study was achieved using strict
interpretation of the test. With the standard interpret-
ation (ΔBov-ΔAv ≥ 3 mm), the sensitivity would be
reduced to 60%.
By contrast, in our trial, only a slightly higher sensitiv-
ity was found when applying the SIT in comparison withthe CIT. However, the results showed serious comprom-
ise of the specificity of the SIT in vaccinated animals
prior to challenge (4 of 4 false-positive reactors), which
completely disappeared when using the CIT. These
results are in accordance with those found in another
study performed in a PTB-vaccinated dairy goat herd
free of TB [21]. Similarly, compromise of the specificity
of the SIT in PTB-vaccinated deer has also been
reported [35,36].
Compared with the SIT, the standard IFN-γ assay
seemed to be more robust in terms of specificity. False-
positive results were concentrated at the interval be-
tween weeks 12 and 14, and then disappeared at week
16 when there was not yet a response to M. caprae in-
fection. After 12 wpv, the IFN-γ responses to PPD-A
decreased faster than did those to PPD-B (see Figure 1).
As a consequence, 60% of the animals were false-
positive “bovine reactors” at week 14. More long-term
trials must be performed to study the kinetics of the
IFN-γ response to Map vaccination.
Encouragingly, the sensitivity obtained for the standard
IFN-γ test after M. caprae challenge was very high con-
sidering that elevated whole-blood IFN-γ responses to
PPD-A were previously observed in Map-vaccinated cat-
tle [37]. In this sense, from weeks 18 to 28 (4–14 wpi),
we only detected a masking due to PPD-A in two vacci-
nated animals. However, the high IFN-γ responses
observed in our study (measured shortly after experi-
mental infection) may decrease with the progression of
natural TB infection under field conditions.
In the last decade, much effort has been focused on
the development of novel antigens for bovine TB diagno-
sis that are more sensitive and specific than the avian
and bovine tuberculins. This research has already
resulted in the identification of several antigens, such as
ESAT-6, CFP-10, and Rv3615c, that reduce cross-
reactive immune responses to different mycobacterial
infections or vaccinations in cattle [26,27,38] and goats
[39,40]. In the present study, we showed the capacity of
both E/C and Rv3615c to distinguish PTB-vaccinated
and TB-infected goats. Furthermore, no differences in
sensitivity were observed between the experimental
groups. Importantly, when combining the positive
results of E/C and Rv3615c IFN-γ assays, the sensitivity
was identical to that obtained by the tuberculin-based
IFN-γ assay, which is currently being employed as an an-
cillary test to the skin test in some eradication cam-
paigns. A similar pattern was previously described in
cattle experimentally infected with M. bovis, in which
the sensitivity increased from 77.9% to 91% when con-
sidering the results of Rv3615c and E/C IFN-γ assay
together [27].
By contrast, serological responses to the Map vaccine
were moderate; only one and four vaccinated goats were
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These data are not in agreement with the 50% positivity
previously obtained in PTB-infected goats [41]. Interest-
ingly, a boost effect on the Map ELISA due to CIT
might be found at week 28 (2 weeks after tuberculin
testing) when comparing the results with the test per-
formed at week 14. The boost effect on the IgG response
due to the skin test was previously described in M.
bovis-infected cattle [34] and M. caprae-infected goats
[24].
Vaccination against Map represents an important ad-
vance in controlling PTB and improving the economic
balance of affected farms. Therefore, the pros and cons
of its application must be exhaustively evaluated. An at-
tractive speculation is that the partial protection to TB
infection observed in some PTB-vaccinated animals
could indirectly facilitate the control of TB, although
long-term field studies are required to confirm this per-
spective. Moreover, we have demonstrated that to some
degree, PTB vaccination interfered (after M. caprae in-
fection) with the sensitivity of tuberculin-based TB diag-
nostic tests. However, beyond the first 2 weeks post-
infection, only 5% false-negative results were obtained in
the IFN-γ assay. In addition, these animals reacted posi-
tively in more than 80% of the remaining post-challenge
tests. Thus, considering the collective basis on which TB
tests are usually applied, it is unlikely that an infected
herd could be undiagnosed upon extrapolation to a lar-
ger population. On the other hand, our results confirm
that the interference with the specificity can be fully
overcome by using defined DIVA reagents. Thus, devel-
oping and subsequently introducing these reagents into
routine diagnostics could represent an improvement in
both strategies: control of PTB by vaccination and con-
trol of TB by rapid detection of infected animals.
Methods
Experimental animals
The experiment was carried out in 20 Murciano-
Granadina female goats between 2 and 3 months of age
from a herd free of TB and PTB in the Region of Murcia
(southwest Spain). Before the experiment, goats were
submitted to standard tests for diagnosis of TB: the CIT
and IFN-γ assay (Bovigam™; Prionics AG, Schlieren,
Switzerland). Experimental animals were confirmed to
be negative for both tests. In addition, all goats had
negative results for PTB (Paratub.Serum-S; Institut Pour-
quier, Montpellier, France).
Vaccination and infection
A group of 10 goats was subcutaneously inoculated with a
single dose of 1 ml (2.5 mg/ml) of SilirumW (CZ Veteri-
naria, Porriño, Pontevedra, Spain), a commercial heat-
inactivated and oil-adjuvanted Map vaccine. Another groupof 10 goats was maintained as unvaccinated controls. After
14 weeks, all animals were housed and acclimatized in two
experimental boxes (level 3 biocontainment) for 1 week
prior to experimental infection.
The field strain of M. caprae SB0416 (www.mbovis.
org) was used as the inoculum and was prepared as pre-
viously described [24]. Goats were anesthetized by intra-
venous administration of 4 to 6 mg/kg of propofol
(Propofol LipuroW) and 0.2 mg/kg of midazolam
(DormicumW), and subsequently inoculated with ap-
proximately 1.5 × 103 cfu of M. caprae suspended in 0.5
ml of phosphate-buffered saline (PBS) by the endobron-
chial route [24].
All experimental procedures were approved by the
Animal Welfare Committee of the Universitat Autòn-
oma de Barcelona in agreement with the European
Union Laws for protection of experimental animals.
Sampling and clinical observations
Animals were observed twice daily at feeding time. Prior
to vaccination and infection and every 2 weeks through-
out the experiment, animals were weighed and their rec-
tal temperature was taken and blood samples were
collected from the jugular vein into heparinized blood
tubes for immunological studies.
Diagnostic tests
Skin tests
Skin tests were carried out in all goats at 26 wpv and 12
wpi. Four goats were also tested at 14 wpv (the
remaining goats were not tested to minimize the poten-
tial effect of the intradermal tuberculin inoculation on
the IFN-γ assay). Tests were performed by inoculating
0.1 ml (2500 IU) of bovine (PPD-B) and avian (PPD-A)
tuberculins (Porriño, Pontevedra, Spain) on the left and
the right side of the neck, respectively. The skin-fold
thickness was recorded just before inoculation and after
72 h. Results were interpreted either by considering only
the increase in thickness for PPD-B (as in a single intra-
dermal test, SIT) or for both PPD-B and PPD-A (as in a
comparative intradermal test, CIT). The results were
read with the strict interpretation used in bovine TB
eradication programs. Goats were considered positive to
SIT if the increase in skin-fold thickness at the PPD-B
site was ≥2 mm. For the CIT interpretation, goats were
considered positive if the increase in skin-fold thickness
at the PPD-B site was ≥2 mm and higher than the in-
crease at the PPD-A site.
IFN-γ assay
Whole-blood cultures were performed every 2 weeks in
96-well cell culture plates. Heparinized blood (1 ml per
well) was incubated for 24 h at 37°C and 5% CO2 with
either PPD-B or PPD-A at a final concentration of 10
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Steinheim, Germany) was used as positive control at 10
μg/ml; PBS was used as a negative control. In addition,
at 0, 2, 6, 10, and 14 wpi, the peptide cocktail ESAT-6/
CFP-10 (E/C) and Rv3615c (Animal Health and Veterin-
ary Laboratories Agency, Weybridge, UK) were used at a
final concentration of 5 μg/ml. Plasma supernatants
were collected after centrifugation and transferred to a
96-well plate. The IFN-γ enzyme-linked immunosorbent
assay (ELISA) was performed according to the manufac-
turer’s instructions (Bovigam™). Optical density was
measured at 450 nm (OD450) using a microplate reader
(PowerWave XS; BioTek, Winooski, VT). Results were
expressed as ΔOD450 (OD450 of antigen-stimulated sam-
ple minus OD450 of non-stimulated sample). A result
was positive when ΔOD450 > 0.05, whereas in the case of
the standard test (using PPD-A and PPD-B as stimuli), a
result was positive when ΔOD450 of PPD-B > 0.05 and
OD450 of PPD-B > OD450 of PPD-A.
Map IgG ELISA
Plasma samples were analyzed in duplicate for anti-
bodies to Map with Paratub.Serum-S™ ELISA before vac-
cination (week 0), before infection (week 14), and before
the end of the experiment (week 28). The assay was per-
formed according to the manufacturer’s instructions.
The ELISA reaction was also measured at OD450. The
results were expressed as S/P (%), calculated as (mean of
sample OD450 - mean of negative control OD450)/(mean
of positive control OD450 - mean of negative control
OD450) × 100. According to the criterion described by
the manufacturer, a sample with an S/P of <45% was
considered to be negative, of <55% and ≥45% to be
doubtful, and of ≥55% to be positive.
Post-mortem examination
All goats were euthanized at 14 wpi (28 wpv) with an
overdose of sodium pentobarbital administered intraven-
ously. They were immediately necropsied to assess the
presence and volume of tuberculous lesions in the lungs
and pulmonary LN.
Lungs
Ten percent-buffered formalin was poured into the tra-
chea, which then was tied, and the lungs were subse-
quently immersed in a container with formalin. After
fixation, the lungs were sliced at 4- to 5-mm intervals,
and each slice was photographed. Gross lesions were
analyzed using image analyzer software (ImageJ 1.43u;
National Institutes of Health, USA). The volume of gross
lesions in each slice was calculated by multiplying the
affected area and slice thickness. The total volume of
gross lesions was calculated by adding the partial
volumes of gross lesions obtained for each slice.Lymph nodes
The number of gross lesions and their diameter were
recorded for each LN at the time of necropsy. Data were
recorded by the same pathologist to ensure measurement
consistency. LN pathology scoring was calculated by the
approximated total volume of granulomas per sample,
calculated using the sphere formula (4/3 × π × r3). After
pathological evaluation, the whole LN was processed
for bacterial culture to calculate the bacterial load.Bacterial count
Cranial and caudal mediastinal, tracheobronchial, and
retropharyngeal LN were individually weighed and
homogenized with 10 ml of sterile distilled water using a
tissue homogenizer (Masticator; IUL Instruments, Bar-
celona, Catalonia, Spain). Homogenates were deconta-
minated with a final concentration of 0.35% w/v
hexadecylpyridinium chloride [42] for 15 min with or-
bital shaking. Decontaminated homogenates were centri-
fuged at 2471 × g for 30 min, and pellets were
resuspended in 10 ml of PBS containing 0.05% Tween
80. Aliquots of 0.1 ml of a 10-fold serial dilution of each
homogenate were plated on Middlebrook 7H11 agar
(BD Diagnostics, Sparks, MD). Plates were incubated at
37°C for 28 days, and colonies were then counted and
the bacterial load (cfu/g) for each sample was calculated.Statistical analysis
Student’s unpaired two-sample t-test was used for com-
parisons between the groups in terms of differences in
thickness increases in the CIT, S/P values of Map IgG
ELISA, number of affected lung lobes, logarithm-
transformed data of volumes of gross lesions (log10
mm3), and bacterial loads in the LN (log10 cfu/g). Corre-
lations between pathology and bacterial burden were
assessed using linear regression analysis, whereas the
non-parametric Spearman rank test was used to analyze
correlations between IFN-γ responses (ΔOD450) and
post-mortem data. After cross-sectional analysis, IFN-γ
responses and post-mortem parameters in the resulting
groups were compared by applying the non-parametric
Kruskal-Wallis test and Dunn’s post hoc multiple com-
parison test. The normality of the data and the homo-
geneity of variances between treatment groups were
assessed using the Shapiro-Wilk and Levene tests, re-
spectively. Statistical analysis of the data was performed
using SPSS Statistical Package version 17.0 (IBM Inc.,
Chicago, IL).
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